Statin intolerance in a referral lipid clinic

Journal of Clinical Lipidology

Volumn 10, Issue 4, 2016, Pages 870-879.e3

  Lakey, Wanda C ^a,b   Greyshock, Nicole G ^a   Kelley, Carly E ^a   Siddiqui, Mohammad A ^c   Ahmad, Umar ^d   Lokhnygina, Yuliya V ^e   Guyton, John R ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c Dow International Medical College   (Pakistan)

^d MERCY HOSPITAL OF PITTSBURGH   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Cognitive effects; Myalgia; Myopathy; Statin; Statin intolerance

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABDOMINAL PAIN; ADULT; ALOPECIA; ARTHRALGIA; ARTICLE; ATAXIA; BEHAVIOR DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DIETARY SUPPLEMENT; DRUG RECHALLENGE; EDEMA; FATTY LIVER; FEMALE; FIBROMYALGIA; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; JOINT STIFFNESS; LANGUAGE DISABILITY; LIVER; LIVER DISEASE; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MENIERE DISEASE; MUSCLE DISEASE; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; ORAL BLISTER; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN DISEASE; SKIN EXFOLIATION; SLEEP DISORDER; TREMOR; URTICARIA; ANTIBODY SPECIFICITY; BLOOD; COUNSELING; MIDDLE AGED; OUTPATIENT DEPARTMENT; PATIENT REFERRAL; STATISTICS AND NUMERICAL DATA;

AMBULATORY CARE FACILITIES; COHORT STUDIES; COUNSELING; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; ORGAN SPECIFICITY; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 84990925782     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.03.004     Document Type: Article

References (30)

1. 1 Stone, N.J., Robinson, J., Lichtenstein, A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:25 Suppl 2 (2014), S1–S45.
2. 2 Jacobson, T.A., Ito, M.K., Maki, K.C., et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – full report. J Clin Lipidol 9 (2015), 129–169.
3. 3 Cohen, J.D., Brinton, E.A., Ito, M.K., Jacobson, T.A., Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 6 (2012), 208–215.
4. 4 Ellis, J.J., Erickson, S.R., Stevenson, J.G., Bernstein, S.J., Stiles, R.A., Fendrick, A.M., Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 19 (2004), 638–645.
5. 5 Zhang, H., Plutzky, J., Skentzos, S., et al. Discontinuation of statin in routine care settings. Ann Intern Med 158 (2013), 526–534.
6. 6 Ganga, H.V., Slim, H.B., Thompson, P.D., A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 168 (2014), 6–15.
7. 7 Rosenson, R.S., Baker, S.K., Jacobson, T.A., Kopecky, S.L., Parker, B.A., An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 8 (2014), S58–S71.
8. 8 Bruckert, E., Hayem, G., Dejager, S., Yau, C., Begaud, B., Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - The Primo Study. Cardiovasc Drugs Ther 19 (2005), 403–414.
9. 9 Jacobson, T., NLA Task Force on Statin Safety - 2014 Update. J Clin Lipidol 8 (2014), S1–S4.
10. 10 Guyton, J.R., Bays, H.E., Grundy, S.M., Jacobson, T.A., An assessment by the Statin Intolerance Panel: 2014 update. J Clin Lipidol 8 (2014), S72–S81.
11. 11 Parker, B.A., Capizzi, J.A., Grimaldi, A.S., et al. Effect of statins on skeletal muscle function. Circulation 127 (2013), 96–103.
12. 12 Thompson, P.D., Zmuda, J.M., Domalik, L.J., Zimet, R.J., Staggers, J., Guyton, J.R., Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46 (1997), 1206–1210.
13. 13 Mampuya, W.M., Frid, D., Rocco, M., et al. Treatment strategies in patients with statin intolerance: The Cleveland Clinic experience. Am Heart J 166 (2013), 597–603.
14. 14 Cham, S., Evans, M.A., Denenberg, J.O., Golomb, B.A., Statin-associated muscle-related adverse events: a case series of 354 patients. Pharmacotherapy 30 (2010), 541–553.
15. 15 Evans, M.A., Golomb, B.A., Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 29 (2009), 800–811.
16. 16 Laufs, U., Schmagal, H., März, W., Statin intolerance. Curr Opin Lipidol 26 (2015), 492–501.
17. 17 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42 (2009), 377–381.
18. 18 Fung, E.C., Crook, M.A., Statin myopathy: a lipid clinic experience on the tolerability of statin rechallenge. Cardiovasc Ther 30 (2012), e212–e218.
19. 19 Marie, I., Delafenêtre, H., Massy, N., Thuillez, C., Noblet, C., Network of the French Pharmacovigilance Centers: Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990-2005 and review of the literature. Arthritis Rheum 59 (2008), 367–372.
20. 20 Mikus, C.R., Boyle, L.J., Borengasser, S.J., et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 62 (2013), 709–714.
21. 21 Moriarty, P.M., Thompson, P.D., Cannon, C.P., et al. Efficacy and safety of alirocumab versus ezetimibe in statin-intolerant patients, with a statin re-challenged arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 9 (2015), 758–769.
22. 22 Wagstaff, L.R., Mitton, M.W., Arvik, B.M., Doraiswamy, P.M., Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23 (2003), 871–880.
23. 23 FDA expands advice on statin risks. Available at: http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM293705.pdf. Accessed December 29, 2014.
24. 24 Rojas-Fernandez, C.H., Cameron, J.C., Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 46 (2012), 549–557.
25. 25 Richardson, K., Schoen, M., French, B., et al. Statins and cognitive function: a systematic review. Ann Intern Med 159 (2013), 688–697.
26. 26 Swiger, K.J., Manalac, R.J., Blumenthal, R.S., Blaha, M.J., Martin, S.S., Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects. Mayo Clin Proc 88 (2013), 1213–1221.
27. 27 Rojas-Fernandez, C.H., Goldstein, L.B., Levey, A.I., Taylor, B.A., Bittner, V., The National Lipid Association's Safety Task Force: An assessment by the Statin Cognitive Safety Task Force: 2014 update. J Clin Lipidol 8:3 Suppl (2014), S5–S16.
28. 28 Cohen, D.E., Anania, F.A., Chalasani, N., National Lipid Association Statin Safety Task Force Liver Expert Panel. Am J Cardiol 97:8A (2006), 77C–81C.
29. 29 Greaves, M.W., Chronic urticaria. N Engl J Med 332 (1995), 1767–1772 Erratum in: N Engl J Med 1995;333:1091.
30. 30 Joy, T.R., Monjed, A., Zou, G.Y., Hegele, R.A., McDonald, C.G., Mahon, J.L., N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 160 (2014), 301–310.